>I would like opinions on DYAX<
DYAX is a pretty interesting company, IMO. You’ve laid out the pros and cons nicely, but I could swear you mentioned Jerini the first time I read your post. Did you edit it?
In any event, DX-88 has competition from Jerini/ABT and also from Pharming. HAE is an orphan indication, so something’s gotta give and I have no idea how it will shake out. (As a GTCB investor, I’m rooting for Pharming.)
>DX-88 for CABG(?)<
The question mark is deserved, IMO, because this is a high-risk venture. Risky enough that even GENZ wanted no part of it and DYAX has to date been unable to secure a new partner. I would not ascribe much value to this program until there is a partner and more clinical data.
At an enterprise value of ~$100M, I’m neutral on DYAX. I think the company has some buyout vig and the income stream from their phage royalties could prevent a total collapse even if DX-88 fails. I’d be considerably more interested in buying in the $50-75M range than I am at $100M. Regards, Dew
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
